drugset / Trial / NCT01394679

A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer

NCT01394679

Phase 3 Not yet recruiting 154 enrolled Cell>Point LLC
Non-randomizedSequentialOpen-labelDiagnostic

Summary

The purpose of this study is to determine if the images of the primary lesions of lung cancer and any metastatic lesions seen from the investigational SPECT/CT 99mTC-EC-DG scans are the same as the PET/CT 18F-FDG scans.

Timeline

Start
2025-05-01
Primary completion
2025-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator 18F-FDG Diagnostic / imaging agent 370 mbq
Comparator 18F-FDG Diagnostic / imaging agent 740 mbq
Subject TECHNETIUM TC-99M ETHYLENE-DICYSTEINE-DEOXYGLUCOSE Unknown 1 mg Intravenous
Subject TECHNETIUM TC-99M ETHYLENE-DICYSTEINE-DEOXYGLUCOSE Unknown 925 mbq Intravenous

Indications